A5046408523- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Treatment of Major Depression
- Child and Adolescent Psychosocial and Emotional Development
- Tryptophan and brain disorders
- Mental Health Research Topics
- Stress Responses and Cortisol
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Functional Brain Connectivity Studies
- Posttraumatic Stress Disorder Research
- Neurotransmitter Receptor Influence on Behavior
- Heart Rate Variability and Autonomic Control
- Healthcare professionals’ stress and burnout
- Perfectionism, Procrastination, Anxiety Studies
- Cardiac Health and Mental Health
- Mental Health and Psychiatry
- Attention Deficit Hyperactivity Disorder
- Diet and metabolism studies
- Obsessive-Compulsive Spectrum Disorders
- Mental Health Treatment and Access
- Maternal Mental Health During Pregnancy and Postpartum
- Psychiatric care and mental health services
- Neural and Behavioral Psychology Studies
- Eating Disorders and Behaviors
- Innovations in Medical Education
Perron Institute for Neurological and Translational Science
2025
North Metropolitan Health Service
2023-2025
Government of Western Australia Department of Health
2015-2025
The University of Western Australia
2016-2025
Government of Western Australia
2023-2024
Sir Charles Gairdner Hospital
2013-2024
Queen Elizabeth II Medical Centre
2005-2015
RWTH Aachen University
2015
Jülich Aachen Research Alliance
2015
Duke University
2015
Background The importance of the neurotransmitter serotonin (5-HT) in pathophysiology anxiety is well known. A key role for postsynaptic 5-HT 1A receptors has recently been suggested studies genetic knockout mice. Aims To measure receptor binding patients with panic disorder untreated state and after recovery on treatment selective reuptake inhibitors (SSRIs). Method Nine symptomatic disorder, seven recovered SSRI medication nineteen healthy volunteers underwent a single positron emission...
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for treatment-resistant depression (TRD), but phase 3 of are needed. Aims To assess the acute efficacy and safety 4-week course subcutaneous in participants with TRD. Trial registration: ACTRN12616001096448 at www.anzctr.org.au . Method This 3, double-blind, randomised, active-controlled multicentre trial was conducted seven mood disorders centres Australia New Zealand. Participants received twice-weekly...
Anxiety disorders are very prevalent and often persistent mental disorders, with a considerable rate of treatment resistance which requires regulatory clinical trials innovative therapeutic interventions. However, an explicit definition treatment-resistant anxiety (TR-AD) informing such is currently lacking. We used Delphi method-based consensus approach to provide internationally agreed, consistent clinically useful operational criteria for TR-AD in adults. Following summary the current...
The field of pharmacogenetics (PGx) is experiencing significant growth, with increasing evidence to support its application in psychiatric care, suggesting potential personalize treatment plans, optimize medication efficacy, and reduce adverse drug reactions. However, the perceived utility practicability PGx for youth remains underexplored. This study investigated barriers attitudes Australian young adults towards implementation testing guide antidepressant primary care. Semi-structured...
Background Anxiety disorders and treatment-resistant major depressive disorder (TRD) are often comorbid. Studies suggest ketamine has anxiolytic antidepressant properties. Aims To investigate if subcutaneous racemic ketamine, delivered twice weekly for 4 weeks, reduces anxiety in people with TRD. Method The Ketamine Adult Depression Study was a multisite 4-week randomised, double-blind, active (midazolam)-controlled trial. study initially used fixed low dose (0.5 mg/kg, cohort 1), before...
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research development novel therapies psychiatric disorders, as well promising results contemporary studies. In this Viewpoint, we reflect upon the 'Clinical Memorandum on Psychedelics' recently released Royal Australian New Zealand College Psychiatrists note subsequent developments including...
The neurobiological basis of panic disorder has not been clearly established, although a role for serotonin (5-HT) postulated. It is clear that drugs which increase 5-HT neurotransmission are effective in treating the condition but how they do so remains point debate. aim this study was to determine if lowering brain activity using technique tryptophan depletion provoked short-term relapse symptoms patients with who had responded drug treatment. Fourteen treatment selective reuptake...
Objective: This study investigated the profile of emotion dysregulation in Bipolar Disorder (BD) and compared it to Unipolar Depression, Anxiety, Healthy control groups. Methods: 148 euthymic patients diagnosed with BD (n = 48), Depressive disorder 50), Anxiety a Control (HC) group 48) were evaluated using Difficulties Emotion Regulation Scale (DERS). The DERS yields total score addition scores on six subcomponents believed encapsulate construct. Results: Compared healthy group, all clinical...
Due to its rapid antidepressant effect, ketamine has recently been clinically translated for people with treatment-resistant depression. However, cognitive profile remains unclear, particularly repeated and higher doses. In the present study, we report results from a recent large multicentre randomised controlled trial, Ketamine Adult Depression Study (KADS). this randomised, double-blind, active-controlled, parallel group, phase 3 trial study investigated potential changes following...
Abstract Two-related studies are presented here, detailing our early experience with benzodiazepine-dependent patients treated a four-day flumazenil infusion using novel delivery technique. Patients long-term benzodiazepine dependence who attended the Australian Medical Procedures Research Foundation (AMPRF, Perth, Australia) for treatment were recruited these studies. Self-reported psychological and physical symptoms, as well objective vital signs data collected at intervals before, during...
Objective: There is evidence that mood disorders are associated with impaired parasympathetic nervous system function and consequently increased morbidity mortality. Our study addresses whether this impairment persists into remission in unipolar bipolar disorders. Methods: Heart Rate Variability was measured groups of subjects during remission, Bipolar Affective Disorder I ( n = 29), recurrent Major Depressive 41) a healthy control group 38), the bedtime period. Results: found to be lower...
As a stand-alone intervention, saffron has efficacy for the treatment of mild-to-moderate depression. However, research as an adjunct agent is limited.The effects to pharmaceutical antidepressants in adults with persistent depression was investigated.In this eight-week, randomised, double-blind, placebo-controlled study, depression, currently taking antidepressant were given placebo or extract (affron®, 14 mg b.i.d.). Primary outcome measures included clinician-rated Montgomery-Åsberg...